Replies to post #55276 on OWC Pharmaceutical Research Corp (OWCP)

[Rhinegold]

Ugh, I guess you don't know that TEVA (with a Market Cap at $39 Billion) already offered a buyout OWCP in 2015 but OWCP, No thanks we can do better. You know that right?

So to re-cap, (OWCP) rejected a (I "HEARD" my opinion ) a $6.5 Billion buy of our patents but they said, No thanks we can do better.

So, that isn't "LOL" it is "Oh sh!T" $$$$$$$$$$

----------------

In case any of you missed it!


Legal Weed Wildcard #1

Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA), out of Israel, manufactures, markets,
and distributes generic and specialty medicines worldwide. It is currently the world’s largest maker of
“generic” drugs.

Teva has signaled that it wants in on marijuana.
In July of 2015 Teva announced that it planned to acquire rival Allergan Generics for $40.5 billion dollars.

The move made perfect sense. Copaxone, Teva’s lead drug, is going off patent. That means generic
equivalents can be developed and sold, which will siphon away much of the $3.29 billion in revenue
Teva hoped to earn from Copaxone this year. Buying the generic drug maker would help offset some of
those losses.


Teva made another announcement last July that garnered less attention from the press.
The company revealed that it had made a bid to acquire the patents of another Israeli firm, One World
Cannabis (OWC).
One World Cannabis (a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTC:
OWCP)) conducts research and clinical trials into cannabis-based products to treat multiple myeloma,
psoriasis, fibromyalgia, PTSD, migraines, and other ailments.
Again, the move makes perfect sense. To offset declining revenue as its lead drug loses patent
protection, Teva is looking to expand into medical marijuana.
OWC is still in the early stages of drug development, but it has produced some promising results.
According to online news site The Marker, “OWC recently reported a study by the Sheba Medical
Center that showed a 60% reduction of malignant multiple myeloma cells within 24 hours of treatment
using the cannabis plant’s active ingredients.”

Nothing hurts a drug-makers top line as much as having its lead drug go off patent. So expect more
and more Big Pharma players to begin exploring ways to leverage legal cannabis to replace some of
that revenue.

Teva Pharmaceutical has already made an “opening gambit.”
There are other signs that that the Israeli giant is taking a good look at medical marijuana